A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China

ABSTRACT: This is a Phase 1/2a, open-label, multi-center study of JAB-3068 in Patients with advanced solid tumors.This study has two phases: dose escalation phase and dose expansion phase.

DISEASE(S): Other Metastatic Solid Tumors,Nsclc,Non-small Cell Lung Cancer,Esophageal Cancer,Head And Neck Cancer

PROVIDER: 2275986 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR